• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information


Clinical settingSerous effusion samples sent to a cytopathology department between 1999 and 2006.
Participants and Country1234. Germany
Study designRetrospective case series.
Target conditionMalignant or non-malignant. Reference standard was clinical follow up and treatment response.
Follow upNot reported
Propotion of patients with malignancy610/1234 (50%)
Pathology techniquesThe sample was centrifuged then the sediment was smeared and stained with Giesma stain. Immunocytochemistry (3 antibodies: pancytokeratin, HEA125, and calretinin).

From: Guideline chapter 2, Diagnosis

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.